A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
A retrospective study sought to determine the efficacy of dexamethasone in preventing cutaneous reactions associated with pemetrexed-based regimens for pulmonary adenocarcinoma.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
The addition of bevacizumab to erlotinib failed to improve progression-free survival in patients with EGFR-mutant non-small cell lung cancer, a phase 2 trial showed.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Large study shows particular increase in the 50- to 64-year-old age group from 2000 to 2016.
For patients receiving drug therapy, economic burden substantial across lines of therapy.
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Researchers found that the off-label drug recommendations listed in the NCCN Guidelines were indeed supported by robust data.
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.